

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	alogliptin-metformin
Brand Name	Kazano™
Dosage Form(s)	12.5 mg/500 mg, 12.5 mg/850 mg and 12.5 mg/1000 mg in fixed-dose combination tablets
Manufacturer	Takeda Canada Inc.
Submission Review	New Submission
Use Reviewed	Type 2 diabetes mellitus (T2DM)
Common Drug Review (CDR)	Yes. CDR recommended: Do not list . Visit the CDR website for more details: www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SR0367_Kazano_Jan-19-15.pdf
Drug Benefit Council (DBC)	The drug was not reviewed by the DBC.
Drug Coverage Decision	Non-Benefit
Date	May 5, 2015
Reason(s)	Alogliptin-metformin was not reviewed by the DBC because it received a “Do not List” recommendation from the CDR. The Ministry of Health reviewed clinical evidence and pharmacoeconomic reports prepared by the CDR, the Canadian Drug Expert Committee (CDEC) Final Recommendation and Reasons, Clinical Practice Reviews from two specialists and a general practitioner and patient input collected through Your Voice. <ul style="list-style-type: none"> Based on CDR review, the clinical benefit of alogliptin as part of a combination treatment with metformin and a sulfonylurea is uncertain compared to other treatment options. Alogliptin-metformin is not approved by Health Canada for use in combination with a sulfonylurea as is the case with other dipeptidyl peptidase IV (DPP-4) inhibitors. Based on the market prices, alogliptin-metformin is less costly than sitagliptin-metformin, similar to saxagliptin-metformin but more costly than linagliptin-metformin.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) (DBC) gives advice to the Ministry. The DBC looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. [Drug Review Process](#) and [PharmaCare](#) program for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.